Covidien, BioSynthema enter cancer therapy deal

Imaging firm Covidien and biopharmaceutical firm BioSynthema have signed exclusive agreements to develop and commercialize a nuclear medicine therapy for neuroendocrine cancer patients.

Under the terms of the deals, St. Louis-based BioSynthema will gain access to specific Covidien proprietary peptide technology. The license will allow BioSynthema to use the technology with its own technology and clinical research to further develop a targeted radionuclide therapy product.

The new technology utilizes a radiolabeled peptide that targets specific somatostatin receptors on neuroendocrine cancer cells, according to the firms. Covidien Imaging Solutions, also of St. Louis, will have exclusive marketing rights to the resulting cancer therapy technology.

By staff writers
October 18, 2007

Related Reading

Covidien partners with UNSW on imaging agent, October 8, 2007

Covidien emerges from Tyco's shadow with R&D emphasis, August 20, 2007

Covidien makes debut as Tyco spinoff, July 5, 2007

E-Z-EM to fight Tyco lawsuit, July 2, 2007

Tyco Healthcare names Wright as pharma/imaging president, March 20, 2007

Copyright © 2007

Page 1 of 436
Next Page